BeiGene, Ltd. (BEIGF)
OTCMKTS
· Delayed Price · Currency is USD
15.50
0.00 (0.00%)
At close: Sep 3, 2024
BeiGene Revenue
BeiGene had revenue of $929.17M in the quarter ending June 30, 2024, with 56.09% growth. This brings the company's revenue in the last twelve months to $3.10B, up 71.01% year-over-year. In the year 2023, BeiGene had annual revenue of $2.46B with 73.65% growth.
Revenue (ttm)
3.10B
Revenue Growth
+71.01%
P/S Ratio
n/a
Revenue / Employee
309.65K
Employees
10,600
Market Cap
21.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Vireo Growth Inc. | 98.04M |
Medexus Pharmaceuticals Inc. | 108.78M |